Ad-hoc: Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 2025 - for the first time more than EUR 10.7 million revenue in one month

Cantourage Group SE / Key word(s): Development of Sales/Quarterly / Interim Statement
Ad-hoc: Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 2025 - for the first time more than EUR 10.7 million revenue in one month

10-Apr-2025 / 09:03 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. Please note the important information at the end of this announcement.

Ad-hoc: Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 2025 – for the first time more than EUR 10.7 million revenue in one month
Berlin, April 10, 2025 – Cantourage Group SE (hereinafter “Cantourage”, ISIN: DE000A3DSV01, www.cantourage.com), Europe's leading listed medical cannabis company, has completed the strongest quarter in its history: In the first quarter of 2025, the company generated revenues of over EUR 25.6 million – a new record.
In March 2025, the Berlin-based company also generated double-digit monthly sales for the first time: at over EUR 10.7 million, the previous record from December 2024 (EUR 8.5 million) was significantly exceeded.

Demand for Cantourage cannabis flowers continues to grow significantly
The continued strong increase in demand for Cantourage cannabis flowers is clearly reflected in the company's sales performance: In 2024 as a whole, the company generated sales revenues of EUR 51.4 million, which corresponds to an increase of 118 percent compared to the previous year (2023: EUR 23.6 million).

About Cantourage:
Cantourage is a leading European company for the production and distribution of medical cannabis. Cantourage enables growers worldwide to sell products in European medical markets. Founded in 2019, the company works with more than 60 cannabis growers from 18 countries. Cantourage ensures the highest pharmaceutical quality standards along the value chain and offers products in all relevant market segments: dried flowers, extracts, dronabinol and cannabidiol. The company has been listed on the Frankfurt Stock Exchange since November 11, 2022 and is listed under the ticker symbol “HIGH”.

Press contacts:
Pia Senkel | pia.senkel@tonka-pr.com | +49 (0) 173 3702649
Klaas Geller | klaas.geller@tonka-communications.de | +49 (0) 176 74717519

Important information:
This announcement contains information for the purposes of Article 17 of Regulation (EU) No 596/2014 (Market Abuse Regulation).
This announcement does not constitute an offer to the public or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
This ad hoc announcement was published via the electronic information distributor EQS News.

10-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com